Satsuma Pharmaceuticals, Inc.

STSA | $1.1 -0.9% -0.91% 0

(0.0% 1d) (0.0% 1m) (7.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (445.43% volume)
Earnings Calendar: 2023-08-08
Market Cap: $ 36,467,748
http://www.satsumarx.com
Sec Filling | Patents | 17 employees

(US) Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.

migraine treatment

add to watch list Paper trade email alert is off

Press-releases

Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting
Published: 2023-06-15 (Crawled : 12:00) - globenewswire.com
STSA | $1.1 -0.9% -0.91% 0

Health Technology

| Email alert Add to watchlist
sts101 treatment pharmaceuticals meeting migraine

Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine
Published: 2023-05-18 (Crawled : 20:00) - globenewswire.com
STSA | $1.1 -0.9% -0.91% 0

Health Technology

| 2.8% | O: -0.93% H: 0.94% C: 0.0%
sts101 fda treatment pharmaceuticals migraine

Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting
Published: 2023-04-21 (Crawled : 12:20) - globenewswire.com
STSA | $1.1 -0.9% -0.91% 0

Health Technology

| 7.32% | O: 0.49% H: 2.91% C: 0.97%
pharmaceuticals meeting

SNBL to Acquire Satsuma Pharmaceuticals
Published: 2023-04-16 (Crawled : 00:00) - globenewswire.com
STSA | $1.1 -0.9% -0.91% 0

Health Technology

| 59.42% | O: 104.35% H: 4.26% C: -23.4%
pharmaceuticals acquire

Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
Published: 2023-03-28 (Crawled : 22:00) - globenewswire.com
STSA | $1.1 -0.9% -0.91% 0

Health Technology

| 30.95% | O: 5.95% H: 3.51% C: -13.48%
business year pharmaceuticals financial results

Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference
Published: 2023-02-02 (Crawled : 17:00) - biospace.com/
STSA | $1.1 -0.9% -0.91% 0

Health Technology

| 17.57% | O: 0.0% H: 4.53% C: -1.24%
biopharma pharmaceuticals global conference

Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
Published: 2022-12-20 (Crawled : 15:00) - globenewswire.com
STSA | $1.1 -0.9% -0.91% 0

Health Technology

| 35.77% | O: 9.23% H: 7.34% C: -1.63%
sts101 pharmaceuticals program update

Satsuma Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
Published: 2022-11-23 (Crawled : 20:00) - globenewswire.com
STSA | $1.1 -0.9% -0.91% 0

Health Technology

| Email alert Add to watchlist
pharmaceuticals conference

Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of Migraine
Published: 2022-11-14 (Crawled : 12:00) - globenewswire.com
STSA | $1.1 -0.9% -0.91% 0

Health Technology

| -74.03% | O: -82.05% H: 0.0% C: 0.0%
sts101 treatment pharmaceuticals topline trial migraine

Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial
Published: 2022-09-20 (Crawled : 13:20) - biospace.com/
STSA | $1.1 -0.9% -0.91% 0

Health Technology

| -84.1% | O: -1.73% H: 0.0% C: 0.0%
sts101 ongoing pharmaceuticals trial positive results

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001104659-23-070513	4	2023-06-13	2023-06-08	Sell	D	10000	0
0001104659-23-070513	4	2023-06-13	2023-06-08	Sell	U	5914252	0